ข่าวประชาสัมพันธ์ Metastatic Breast Cancer+SciClone Pharmaceuticals
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU(R) (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and are a known driver of resistance to standard endocrine therapy, making these tumors more difficult to treat. This agreement includes undisclosed upfront, milestone payments
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU(R) (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium
ELEVATE and ELECTRA studies were designed with the ob...Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023
This new post hoc analysis of the Phase 3 EMERALD trial evalu...European Commission Approves Menarini Group's ORSERDU(R) (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen...Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU(R) (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer...Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or...Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2-...Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available...Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced...Menarini Progresses Into the Clinic With MEN1611, a PI3K Inhibitor for the Treatment of HER2 Positive Metastatic Breast Cancer
Menarini Ricerche announced today the initiation of the B-PRECISE-01 clinical trial, a multicenter phase Ib study that will evaluate the safety and efficacy of MEN1611 plus...
ภาพข่าว: เครือข่ายมะเร็งเต้านมภาคเหนือตอนบน จัดอบรม “การตรวจคัดกรองและดูแลผู้ป่วยมะเร็งเต้านมระยะแพร่กระจาย”
—
รศ.พญ. อิ่มใจ ชิตาพนารักษ์ หน่วยรังสีรักษาแ...